Xianglong Reference Material Center is affiliated with Changzhou Xianglong Group, a group company specializing in the research, development, production, quality control, and sales of standard materials/standards for life health sciences. With over a decade of brand operation, it has served more than 5,000 clients across markets in Asia, North America, Europe, and South America, facilitating the successful approval of over 4,500 drug varieties. The brand provides over 60,000 standard substances to global clients and has established long-term stable collaborations with official pharmacopeias such as the United States Pharmacopeia, European Pharmacopoeia, and Chinese Pharmacopoeia. It stands as one of the most renowned standard substance brands worldwide, offering products including drug standards, impurity references, metabolites, degradation products, and custom synthesized standards.

Xianglong Group has introduced a synthetic team led by postdoctoral researchers with overseas experience, possessing exceptional capabilities in customizing impurity standards. This team provides brands with a continuous stream of innovative products and technical support.

Longhui Biotechnology, a subsidiary of the group and the production entity of the brand, specializes in the production, quality control, and assignment of standard materials. In 2023, it obtained CNAS 17025 laboratory accreditation, ensuring the provision of high-quality, stable, reliable, and regulatory-compliant products to customers.

Xianglong Pharmaceutical, a subsidiary of the group, has established a seasoned and professional sales service team for the brand. This team is capable of delivering high-quality, end-to-end services—from product quotations to delivery—ensuring an exceptional service experience for clients.